Eurofarma Synapsis boosts scale-up at Leforte Group
Published in: March 13, 2020
and updated in: November 4, 2021
Listen to the text
Stop the audio
Laura is one of the scale-ups accelerated by the Eurofarma program and, through a bot, uses Artificial Intelligence to help manage infection risks in patients
São Paulo, March 2020 – Starting in March, Eurofarma Synapsis — Eurofarma’s acceleration program built in partnership with Endeavor to support entrepreneurship in Latin America and encourage innovation in the health sector — will boost one of its accelerated scale-ups, Laura, with a project that will use Artificial Intelligence to manage infection risks in patients of the Leforte Group, which has three hospitals in the São Paulo Metro area.
The agreement calls for the robot Laura to be used identify and monitor hospitalized patients who are at risk for infection. The software connects electronic patient files to a management dashboard located at the Nursing Center. Every new input on vital signs, in addition to the tests collected in real time, can generate a high-, medium- or low-risk classification, helping the staff prioritize nursing care.
“Laura’s technology allows for data mining, which in turn helps determine the level of risk for each patient. It is an innovative project supported by Eurofarma Synapsis, where we leverage our network to drive business for the accelerated scale-up, and which has great growth potential,” said Helton Pinheiro de Carvalho, executive director of Entrepreneurship and Digital.
“The partnership with Eurofarma is part of an program of excellence for improving the quality of health services, with artificial intelligence and information technology at the core of a new concept of health care that the Leforte Group is pioneering in the supplementary health market. In addition to providing continuous improvement of our processes, this initiative contributes to increasing the levels of prevention and problem-solving that we offer to our clients, which ultimately lead to an improved clinical outcome and, consequently, in the financial predictability that we are looking for in our health care,” said Tiago Damasceno, superintendent of Information Technology at Leforte Group.
“The partnership with Eurofarma is an important step at this moment, as we expand and accelerate Robot Laura, which further reinforces our commitment towards patient care,” added Cristian Rocha, CEO of Laura.
Initially, the robot Laura will be implemented at the Lefort Group units of Morumbi, Liberdade, and Hospital e Maternidade Christóvão da Gama, in Santo André, in the São Paulo Metro area, also offering continuing education, scientific material and improved quality indicators. The solution is expected to reach more hospitals over the course of 2020.
To find out more about the Eurofarma Synapsis program and accelerated and supported initiatives, go to www.eurofarma.com.br/synapsis.
About Leforte Group
Currently, the Leforte Group has three hospitals with a total of 620 beds — two in São Paulo, in the Liberdade and Morumbi districts, and one in Santo André, in the São Paulo Metro area. It also has a specialized Oncology practice in Higienópolis, Alphaville and Osasco, and a Pediatrics unit in Santo Amaro, in addition to clinics in Alphaville and Cotia. Leforte is the Official Hospital of the Brazilian Formula 1 GP.
About Laura
Laura is an innovative technology implemented in hospitals for early detection of clinical risks. Created by systems architect Jac Fressatto after his daughter died from sepsis, the device uses artificial intelligence and cognitive technology to manage routine hospital data and issue alerts. Active since 2016, Laura has had approximately 2.5 million patients connected and reduced hospital mortality rates by 25%. In addition to helping to save 12 lives a day, it also optimizes the time and resources devoted to health care.
About Eurofarma Group
Eurofarma is a health company focused on offering products and services to improve people’s lives with quality, innovation and fair prices across all major pharmaceutical segments: Prescription, Generic, Hospital, Oncology, and Nonprescription Drugs, as well as Veterinary Medicine. In Brazil alone, the company offers 287 different molecules and over 600 products. Eurofarma is a leader in medical prescriptions, serving 30 different specialties and covering 101 therapeutic classes, which account for 89% of retail pharmaceutical sales. The company has the largest sales force in the country, which visits approximately 600,000 doctors monthly.
Founded in 1972 and the first pharmaceutical multinational with 100% Brazilian capital, it has own operations in 20 countries and maintains a major manufacturing park in Brazil, as well as plants in 6 other Latin American countries. The group reported sales of BRL 4.3 billion in 2018 and employs over 6,700 employees.
Eurofarma in social media
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram:@eurofarma_br
São Paulo, March 2020 – Starting in March, Eurofarma Synapsis — Eurofarma’s acceleration program built in partnership with Endeavor to support entrepreneurship in Latin America and encourage innovation in the health sector — will boost one of its accelerated scale-ups, Laura, with a project that will use Artificial Intelligence to manage infection risks in patients of the Leforte Group, which has three hospitals in the São Paulo Metro area.
The agreement calls for the robot Laura to be used identify and monitor hospitalized patients who are at risk for infection. The software connects electronic patient files to a management dashboard located at the Nursing Center. Every new input on vital signs, in addition to the tests collected in real time, can generate a high-, medium- or low-risk classification, helping the staff prioritize nursing care.
“Laura’s technology allows for data mining, which in turn helps determine the level of risk for each patient. It is an innovative project supported by Eurofarma Synapsis, where we leverage our network to drive business for the accelerated scale-up, and which has great growth potential,” said Helton Pinheiro de Carvalho, executive director of Entrepreneurship and Digital.
“The partnership with Eurofarma is part of an program of excellence for improving the quality of health services, with artificial intelligence and information technology at the core of a new concept of health care that the Leforte Group is pioneering in the supplementary health market. In addition to providing continuous improvement of our processes, this initiative contributes to increasing the levels of prevention and problem-solving that we offer to our clients, which ultimately lead to an improved clinical outcome and, consequently, in the financial predictability that we are looking for in our health care,” said Tiago Damasceno, superintendent of Information Technology at Leforte Group.
“The partnership with Eurofarma is an important step at this moment, as we expand and accelerate Robot Laura, which further reinforces our commitment towards patient care,” added Cristian Rocha, CEO of Laura.
Initially, the robot Laura will be implemented at the Lefort Group units of Morumbi, Liberdade, and Hospital e Maternidade Christóvão da Gama, in Santo André, in the São Paulo Metro area, also offering continuing education, scientific material and improved quality indicators. The solution is expected to reach more hospitals over the course of 2020.
To find out more about the Eurofarma Synapsis program and accelerated and supported initiatives, go to www.eurofarma.com.br/synapsis.
About Leforte Group
Currently, the Leforte Group has three hospitals with a total of 620 beds — two in São Paulo, in the Liberdade and Morumbi districts, and one in Santo André, in the São Paulo Metro area. It also has a specialized Oncology practice in Higienópolis, Alphaville and Osasco, and a Pediatrics unit in Santo Amaro, in addition to clinics in Alphaville and Cotia. Leforte is the Official Hospital of the Brazilian Formula 1 GP.
About Laura
Laura is an innovative technology implemented in hospitals for early detection of clinical risks. Created by systems architect Jac Fressatto after his daughter died from sepsis, the device uses artificial intelligence and cognitive technology to manage routine hospital data and issue alerts. Active since 2016, Laura has had approximately 2.5 million patients connected and reduced hospital mortality rates by 25%. In addition to helping to save 12 lives a day, it also optimizes the time and resources devoted to health care.
About Eurofarma Group
Eurofarma is a health company focused on offering products and services to improve people’s lives with quality, innovation and fair prices across all major pharmaceutical segments: Prescription, Generic, Hospital, Oncology, and Nonprescription Drugs, as well as Veterinary Medicine. In Brazil alone, the company offers 287 different molecules and over 600 products. Eurofarma is a leader in medical prescriptions, serving 30 different specialties and covering 101 therapeutic classes, which account for 89% of retail pharmaceutical sales. The company has the largest sales force in the country, which visits approximately 600,000 doctors monthly.
Founded in 1972 and the first pharmaceutical multinational with 100% Brazilian capital, it has own operations in 20 countries and maintains a major manufacturing park in Brazil, as well as plants in 6 other Latin American countries. The group reported sales of BRL 4.3 billion in 2018 and employs over 6,700 employees.
Eurofarma in social media
Facebook: @eurofarma | LinkedIn: @eurofarma | Instagram:@eurofarma_br